ccRCC PET Imaging Agent Earns FDA Breakthrough Therapy, Fast Track Statuses

◆ ◆ The Wire takeaway

FDA’s accelerated pathway for this imaging agent means you can plan for quicker market entry if you work on kidney cancer diagnostics. This creates a clearer route for investment and partnerships focused on faster clinical validation.